Related Experiment Video

Updated: Jul 11, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Sunitinib

Brian I Rini1

  • 1Cleveland Clinic Taussig Cancer Center, Department of Solid Tumor Oncology and Urology, 9500 Euclid Avenue/Desk R35, Cleveland, Ohio 44195, USA. rinib2@ccf.org

Expert Opinion on Pharmacotherapy
|October 12, 2007
PubMed

Insights

Sunitinib, a receptor tyrosine kinase inhibitor, shows significant antitumor effects in advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Further research is needed to optimize its use in various solid tumors.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Sunitinib targets receptor tyrosine kinases involved in tumor angiogenesis, such as the vascular endothelial growth factor (VEGF) receptor.
  • In vitro and murine models demonstrate potent inhibition and antiangiogenic effects of sunitinib.

Purpose of the Study:

  • To summarize the efficacy and tolerability of sunitinib in clinical studies.
  • To highlight its approved indications and ongoing investigations in solid tumors.

Main Methods:

  • Review of in vitro and murine model data.
  • Analysis of human clinical trial results for sunitinib dosing and efficacy.
  • Summary of regulatory approvals and ongoing investigations.

Main Results:

  • Sunitinib is a well-tolerated small-molecule inhibitor at a 50 mg daily intermittent dose.
  • Significant antitumor activity observed in advanced renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).

Conclusions:

  • Sunitinib is approved for RCC and GIST, demonstrating significant clinical benefit.
  • Ongoing investigations explore sunitinib's potential across a wider range of solid tumors.
  • Further research is required to fully optimize sunitinib's therapeutic utility.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...